BioCentury
ARTICLE | Clinical News

ITCA 650: Additional Phase III data

October 6, 2014 7:00 AM UTC

Additional data from the open-label, U.S. Phase III FREEDOM-1 HBL trial in 59 Type II diabetics with an HbA1c of >10% and <=12% not controlled on 0-3 oral diabetes drugs showed that ITCA 650 led to a mean reduction in HbA1c from baseline of 3.4% at week 39. Additionally, 25% of patients achieved an HbA1c <7% at week 39. Patients received once-daily 20 Ug ITCA 650 for the first 3 months followed by once-daily 60 Ug ITCA 650 for 6 months. Intarcia said the data will be submitted for presentation at the American Diabetes Association meeting in Boston in June. Last June, Intarcia reported interim 13-, 19- and 26-week data from the trial (see BioCentury, June 23). ...